Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.
Ontology highlight
ABSTRACT: The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to induction therapy, which causes tumor progression and early death in high-risk patients, and managing chemotherapy-resistant relapses, which can occur years after the initial diagnosis. Identifying and validating novel therapeutic targets is essential to improve treatment. Delineating and deciphering specific functions of single histone deacetylases in neuroblastoma may support development of targeted acetylome-modifying therapeutics for patients with molecularly defined high-risk neuroblastoma profiles. We show here that HDAC11 depletion in
SUBMITTER: Thole TM
PROVIDER: S-EPMC5386552 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA